Moderna Beats Q1 Earnings Estimates on Strong International Sales

Moderna reported a narrower adjusted loss of $1.18 per share, exceeding the consensus of $2.45 loss. The company also beat revenue expectations with $389 million. However, the stocks fell 2.05% due to a $2.22 per share litigation settlement charge.

Moderna delivered a strong first quarter, beating earnings estimates despite a litigation charge. The company reported a narrower adjusted loss of $1.18 per share, outperforming the expected loss of $2.45 . Additionally, revenue exceeded forecasts with $389 million, representing a significant improvement over the consensus of $227.97 million .

However, shares declined 2.05% on Friday due to a $2.22 per share litigation settlement charge. Despite this, Moderna reiterated its 2026 revenue growth guidance of up to 10% and announced progress on its H5 pandemic flu vaccine candidate with a Phase 3 trial launch, which could help mitigate the impact of the settlement charge .

Looking ahead, Moderna reiterated guidance for up to 10% full-year revenue growth in 2026, with geographic mix expected at roughly 50% US and 50% international — a meaningful shift from its historically US-centric revenue base. The company ended Q1 with $7.5 billion in cash and investments and projects year-end cash of $4.5–$5.0 billion, reflecting a carefully managed burn rate as it expands into RSV, flu, and oncology mRNA programs. Progress on the H5 pandemic flu vaccine candidate adds an emergency preparedness revenue stream that governments have historically funded generously regardless of COVID trends.

Moderna Beats Q1 Earnings Estimates on Strong International Sales

Related Stocks